Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
Last Updated: Thursday, September 23, 2021
According to findings from a recent analysis of the Netherlands Cancer Registry, patients with diffuse large B-cell lymphoma who received rituximab biosimilars in combination with R-CHOP chemotherapy experienced similar 3-year overall survival (73% [95% CI: 72%-74%]) as patients who received rituximab plus R-CHOP (73% [95% CI: 70%-76%]; P = .182).
Advertisement
News & Literature Highlights